Boston Scientific Files 8-K Report
Ticker: BSX · Form: 8-K · Filed: Apr 4, 2024 · CIK: 885725
| Field | Detail |
|---|---|
| Company | Boston Scientific CORP (BSX) |
| Form Type | 8-K |
| Filed Date | Apr 4, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-k
Related Tickers: BSX
TL;DR
BSX filed a standard 8-K, no major news.
AI Summary
On April 3, 2024, Boston Scientific Corporation (BSX) filed an 8-K report detailing an "Other Event." The filing does not contain specific financial figures or new material agreements, but rather standard corporate reporting information.
Why It Matters
This filing indicates routine corporate activity and does not represent a significant event or change for investors.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain any new material information that would impact the company's risk profile.
Key Players & Entities
- Boston Scientific Corporation (company) — Registrant
- BSX (company) — Ticker Symbol
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report an 'Other Event' as of April 3, 2024, which is a standard corporate disclosure.
When was this 8-K report filed?
This 8-K report was filed on April 4, 2024.
What is the principal executive office address for Boston Scientific Corporation?
The address of the principal executive offices is 300 Boston Scientific Way, Marlborough, Massachusetts 01752-1234.
What is the state of incorporation for Boston Scientific Corporation?
Boston Scientific Corporation is incorporated in Delaware.
Does this filing announce any new financial results or material agreements?
No, this filing is categorized under 'Other Events' and does not appear to announce new financial results or material agreements based on the provided text.
Filing Stats: 1,432 words · 6 min read · ~5 pages · Grade level 17.4 · Accepted 2024-04-04 07:19:11
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share BSX New York Stock
Filing Documents
- bsx-20240403.htm (8-K) — 36KB
- 0000885725-24-000037.txt ( ) — 198KB
- bsx-20240403.xsd (EX-101.SCH) — 3KB
- bsx-20240403_def.xml (EX-101.DEF) — 15KB
- bsx-20240403_lab.xml (EX-101.LAB) — 27KB
- bsx-20240403_pre.xml (EX-101.PRE) — 16KB
- bsx-20240403_htm.xml (XML) — 4KB
01 OTHER EVENTS
ITEM 8.01 OTHER EVENTS As previously disclosed, on January 8, 2024, Boston Scientific Corporation, a Delaware corporation (the " Company "), entered into an Agreement and Plan of Merger (the " Merger Agreement ") with Sadie Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (" Merger Sub "), and Axonics, Inc., a Delaware corporation (" Axonics "), providing for the merger of Merger Sub with and into Axonics (the " Merger "), with Axonics surviving the Merger as a wholly owned subsidiary of the Company. Consummation of the Merger is subject to certain conditions, including the expiration or termination of any waiting period (and any extension thereof) applicable to the consummation of the Merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the " HSR Act "), and any agreement with a governmental authority not to consummate the Merger . On April 3, 2024, the Company and Axonics each received a request for additional information (the " Second Request ") from the U.S. Federal Trade Commission (the " FTC ") in connection with the FTC's review of the Merger. The issuance of the Second Request extends the waiting period under the HSR Act until 30 days after both the Company and Axonics have substantially complied with the Second Request, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. The Company and Axonics expect to promptly respond to the Second Request and to continue to work cooperatively with the FTC in its review of the Merger. The Merger is now expected to be completed in the second half of 2024, subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction (or waiver) of other customary closing conditions. Cautionary Statement Regarding Forward-Looking Statements Certain statements that we may make from time to time, including statements contained in this Current Report on Form 8-K and information inc